These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 33383399)

  • 1. Radiological response to nivolumab in patients with hepatocellular carcinoma: A multicenter analysis of real-life practice.
    Rimola J; Da Fonseca LG; Sapena V; Perelló C; Guerrero A; Simó MT; Pons M; De La Torre-Aláez M; Márquez L; Calleja JL; Lledó JL; Varela M; Mínguez B; Sangro B; Matilla A; Torres F; Ayuso C; Bruix J; Reig M
    Eur J Radiol; 2021 Feb; 135():109484. PubMed ID: 33383399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis.
    Kudo M; Matilla A; Santoro A; Melero I; Gracián AC; Acosta-Rivera M; Choo SP; El-Khoueiry AB; Kuromatsu R; El-Rayes B; Numata K; Itoh Y; Di Costanzo F; Crysler O; Reig M; Shen Y; Neely J; Tschaika M; Wisniewski T; Sangro B
    J Hepatol; 2021 Sep; 75(3):600-609. PubMed ID: 34051329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh class B cirrhosis: Safety and clinical outcomes in a retrospective case series.
    Thiruvengadam S; Bauer KE; Bracci PM; Keenan BP; Behr SC; Gordan JD; Kelley RK
    Cancer; 2019 Sep; 125(18):3234-3241. PubMed ID: 31154669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.
    El-Khoueiry AB; Sangro B; Yau T; Crocenzi TS; Kudo M; Hsu C; Kim TY; Choo SP; Trojan J; Welling TH; Meyer T; Kang YK; Yeo W; Chopra A; Anderson J; Dela Cruz C; Lang L; Neely J; Tang H; Dastani HB; Melero I
    Lancet; 2017 Jun; 389(10088):2492-2502. PubMed ID: 28434648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative assessment of standard and immune response criteria for evaluation of response to PD-1 monotherapy in unresectable HCC.
    Lewis S; Cedillo MA; Lee KM; Bane O; Hectors S; Ma W; Wang P; Stocker D; Morris DV; Pinato D; Sung M; Marron T; Schwartz M; Taouli B
    Abdom Radiol (NY); 2022 Mar; 47(3):969-980. PubMed ID: 34964909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Local Tumor Control and Patient Outcome Using Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: iRECIST as a Potential Substitute for Traditional Criteria.
    Vernuccio F; Godfrey D; Meyer M; Williamson HV; Salama JK; Niedzwiecki D; Stephens SJ; Ronald J; Palta M; Marin D
    AJR Am J Roentgenol; 2019 Dec; 213(6):1232-1239. PubMed ID: 31613663
    [No Abstract]   [Full Text] [Related]  

  • 7. Feasibility and safety of nivolumab in advanced hepatocellular carcinoma: real-life experience from three German centers.
    Finkelmeier F; Czauderna C; Perkhofer L; Ettrich TJ; Trojan J; Weinmann A; Marquardt JU; Vermehren J; Waidmann O
    J Cancer Res Clin Oncol; 2019 Jan; 145(1):253-259. PubMed ID: 30374657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CT imaging findings in patients with advanced hepatocellular carcinoma treated with sorafenib: Alternative response criteria (Choi, European Association for the Study of the Liver, and modified Response Evaluation Criteria in Solid Tumor (mRECIST)) versus RECIST 1.1.
    Gavanier M; Ayav A; Sellal C; Orry X; Claudon M; Bronowicki JP; Laurent V
    Eur J Radiol; 2016 Jan; 85(1):103-112. PubMed ID: 26724654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study.
    Fessas P; Kaseb A; Wang Y; Saeed A; Szafron D; Jun T; Dharmapuri S; Rafeh Naqash A; Muzaffar M; Navaid M; Khan U; Lee C; Bulumulle A; Yu B; Paul S; Nimkar N; Bettinger D; Benevento F; Hildebrand H; Pressiani T; Abugabal YI; Personeni N; Huang YH; Rimassa L; Ang C; Marron T; Pinato DJ
    J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32868393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Radiological Tumor Response Based on iRECIST and RECIST 1.1 in Metastatic Clear-Cell Renal Cell Carcinoma Patients Treated with Programmed Cell Death-1 Inhibitor Therapy.
    Zheng B; Shin JH; Li H; Chen Y; Guo Y; Wang M
    Korean J Radiol; 2021 Mar; 22(3):366-375. PubMed ID: 33289356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of RECIST and iRECIST criteria in patients with advanced lung cancer treated with nivolumab.
    Singla R; Jajodia A; Agrawal RK; Rao A; Pasricha S; Batra U
    J Cancer Res Ther; 2023; 19(5):1212-1218. PubMed ID: 37787285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis.
    Yau T; Hsu C; Kim TY; Choo SP; Kang YK; Hou MM; Numata K; Yeo W; Chopra A; Ikeda M; Kuromatsu R; Moriguchi M; Chao Y; Zhao H; Anderson J; Cruz CD; Kudo M
    J Hepatol; 2019 Sep; 71(3):543-552. PubMed ID: 31176752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-dose nivolumab in advanced hepatocellular carcinoma.
    Chen YH; Wang CC; Chen YY; Wang JH; Hung CH; Kuo YH
    BMC Cancer; 2022 Nov; 22(1):1153. PubMed ID: 36348292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomised phase II trials comparing nintedanib vs sorafenib.
    Meyer T; Palmer DH; Cheng AL; Hocke J; Loembé AB; Yen CJ
    Liver Int; 2017 Jul; 37(7):1047-1055. PubMed ID: 28066978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-life multi-center retrospective analysis on nivolumab in difficult-to-treat patients with advanced hepatocellular carcinoma.
    De Wilde N; Vonghia L; Francque S; De Somer T; Bagdadi A; Staub E; Lambrechts J; Bucalau AM; Verset G; Van Steenkiste C
    World J Hepatol; 2022 Aug; 14(8):1608-1620. PubMed ID: 36157862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world comparison of pembrolizumab and nivolumab in advanced hepatocellular carcinoma.
    Chen YH; Tsai CH; Chen YY; Wang CC; Wang JH; Hung CH; Kuo YH
    BMC Cancer; 2023 Aug; 23(1):810. PubMed ID: 37644388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma.
    Edeline J; Boucher E; Rolland Y; Vauléon E; Pracht M; Perrin C; Le Roux C; Raoul JL
    Cancer; 2012 Jan; 118(1):147-56. PubMed ID: 21713764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Solid Tumor Treatment Response Observed in Clinical Practice With Response Reported in Clinical Trials.
    Feinberg BA; Zettler ME; Klink AJ; Lee CH; Gajra A; Kish JK
    JAMA Netw Open; 2021 Feb; 4(2):e2036741. PubMed ID: 33630085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inter-operator variability and source of errors in tumour response assessment for hepatocellular carcinoma treated with sorafenib.
    Tovoli F; Renzulli M; Negrini G; Brocchi S; Ferrarini A; Andreone A; Benevento F; Golfieri R; Morselli-Labate AM; Mastroroberto M; Badea RI; Piscaglia F
    Eur Radiol; 2018 Sep; 28(9):3611-3620. PubMed ID: 29633000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Role of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review and Pooled Analysis of 2,402 Patients.
    Ziogas IA; Evangeliou AP; Giannis D; Hayat MH; Mylonas KS; Tohme S; Geller DA; Elias N; Goyal L; Tsoulfas G
    Oncologist; 2021 Jun; 26(6):e1036-e1049. PubMed ID: 33314549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.